MCT1 expression is increased in infiltrating leukocytes and reactive astrocytes in active MS lesions, and MCT2 expression is decreased in inactive MS lesions (Nijland et al., 2014). The gene discussed is SLC16A1; the disease is myeloid sarcoma.